MIT's Technology Review offers a rundown this week of several pharma projects using the genes of healthy people to inspire new cholesterol-lowering drugs.

Four companies, Pfizer, Amgen, and Alnylam, and a firm called Regeneron, are all developing drugs targeting the gene PCSK9, Tech Review's Susan Young writes.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Alnylam's RNAi-based therapy Onpattro, according to Stat News.

Harvard Medical School's Seth Cassel and Cigall Kadoch argue in a Baltimore Sun op-ed that the recent TAILORx trial shows the potential of genomic-based medicine.

Researchers in the UK are working on using gene drives to control malaria-carrying mosquitoes, the Telegraph reports.

In PLOS this week: genetic architecture mediating gene expression, metabolomic patterns in multiple myeloma, and more.